Key result
Synergist ablation provides valuable insights into disease-specific regulatory mechanisms of skeletal muscle hypertrophy in rodent models, though hypertrophy gains are attenuated in diseased animals.
Why the study?
Although extensively characterized in healthy animals, the potential applications of synergist ablation to study skeletal muscle hypertrophy mechanisms in rodent disease models remain largely overlooked.
Does synergist ablation induce skeletal muscle hypertrophy and provide mechanistic insights in rodent disease models?
Does synergist ablation induce skeletal muscle hypertrophy and provide mechanistic insights in rodent disease models?
Synergist ablation is a valuable preclinical model for studying skeletal muscle plasticity and resistance training adaptations in various pathological conditions.
Answers are grounded in this paper and cite their sources.
SA models may inform disease-specific hypertrophy mechanisms; leaves open translation to human clinical practice.
Synergist ablation (SA) is a well-established model of mechanical overload-induced hypertrophy in rodents, commonly used to infer skeletal muscle adaptation to resistance training in humans. Given the critical role of skeletal muscle atrophy in chronic conditions such as neuromuscular, metabolic, and cardiopulmonary disorders, SA represents a promising preclinical tool to study muscle hypertrophy mechanisms in pathological states. However, although extensively characterized in healthy animals, the potential applications of SA in disease models remain largely overlooked. This Mini-Review summarizes existing studies employing SA in rodent disease models, highlighting the diverse hypertrophic responses observed across conditions, including Duchenne muscular dystrophy, obesity, diabetes, cancer cachexia, and chronic kidney disease. Although hypertrophy gains are generally attenuated in diseased animals compared to healthy controls, SA-induced overload provides valuable insights into disease-specific regulatory mechanisms, including alterations in intracellular signaling, fiber type transitions, and disease phenotype. We also discuss the strengths and limitations of SA as a preclinical model for resistance training in disease contexts and propose its broader adoption for mechanistic investigations into skeletal muscle plasticity under pathological conditions.
No takes yet. Share an insight, caveat, or question.
Sarto et al. (2025) conducted a review in Skeletal muscle hypertrophy in rodent disease models. Synergist ablation vs. Healthy controls was evaluated. Synergist ablation provides valuable insights into disease-specific regulatory mechanisms of skeletal muscle hypertrophy in rodent models, though hypertrophy gains are attenuated in diseased animals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: